Total trials
1,654
Active
560
Phase 3
288
Total enrollment
3,246,648
Pipeline matrix
Showing 40 of 487 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Penehyclidine hydrochloride | — | — | — | — | — | 1 | |
| vnacicizumab | — | — | — | — | — | 1 | |
| normal saline | — | — | — | 5 | |||
| Cisplatin | — | — | 62 | ||||
| Toripalimab | — | — | — | 36 | |||
| Capecitabine | — | — | — | — | 37 | ||
| Sintilimab | — | — | 36 | ||||
| Bevacizumab | — | — | — | 30 | |||
| Gemcitabine | — | — | — | 30 | |||
| Tislelizumab | — | — | — | 16 | |||
| Oxaliplatin | — | — | — | — | 25 | ||
| Concurrent chemotherapy | — | — | 23 | ||||
| Lenvatinib | — | — | — | 31 | |||
| Camrelizumab | — | — | — | 23 | |||
| Chemotherapy | — | — | — | 20 | |||
| Carboplatin | — | — | — | — | 15 | ||
| Paclitaxel | — | — | — | — | 10 | ||
| PD-1 blocking antibody | — | — | — | — | 6 | ||
| Becotatug Vedotin | — | — | — | 5 | |||
| Adebrelimab | — | — | — | — | 5 | ||
| Pucotenlimab | — | — | — | — | 5 | ||
| Cadonilimab | — | — | — | 6 | |||
| Docetaxel | — | — | — | 15 | |||
| PD-1 antibody | — | — | — | — | 13 | ||
| Temozolomide | — | — | — | 7 | |||
| 5-Fluorouracil | — | — | — | — | 6 | ||
| Anlotinib | — | — | — | — | 6 | ||
| Fruquintinib | — | — | — | — | 4 | ||
| Serplulimab | — | — | — | — | 4 | ||
| Apatinib | — | — | — | 17 | |||
| 5-FU | — | — | — | — | 7 | ||
| Fluorouracil | — | — | — | — | 7 | ||
| mFOLFOX6 | — | — | — | — | 7 | ||
| QL1706 | — | — | — | — | 3 | ||
| Consolidative immunotherapy | — | — | — | — | — | 3 | |
| CAPOX | — | — | — | — | 3 | ||
| Adjuvant chemotherapy | — | — | — | — | 7 | ||
| Anlotinib Hydrochloride | — | — | — | 5 | |||
| Pegaspargase | — | — | — | — | 10 | ||
| Nimotuzumab | — | — | — | — | 6 |
447 more active programs hidden
Next readouts
- 2020-07-20
- 2022-04
- 2022-12-30
- 2023-03-15
- 2023-06-15
- 2023-06-25
- 2023-07-01
- 2023-07-20
- 2023-08-30
- 2023-09-01
Top conditions
- Nasopharyngeal Carcinoma140
- Hepatocellular Carcinoma130
- Non-small Cell Lung Cancer41
- Colorectal Cancer39
- Breast Cancer37
- Cataract30
- Rectal Cancer23
- Nasopharyngeal Cancinoma (NPC)22
Frequently asked questions about Sun Yat-sen University
- How many clinical trials does Sun Yat-sen University have on ClinicalTrials.gov?
- Sun Yat-sen University is listed as the lead sponsor on 1,654 clinical trials in ClinicalTrials.gov, 560 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Sun Yat-sen University's trials are in Phase 3?
- 288 of Sun Yat-sen University's trials are in Phase 3, spread across 487 active drug programs.
- What therapeutic areas does Sun Yat-sen University focus on?
- Sun Yat-sen University's most-studied conditions on ClinicalTrials.gov are Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer.
- When are Sun Yat-sen University's next clinical trial readouts?
- Sun Yat-sen University has 10 upcoming primary-completion readouts tracked here; the soonest is “HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC”, expected around 2020-07-20.